-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35

Benzinga·06/30/2026 13:54:56
Listen to the news
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and raises the price target from $30 to $35.